Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis
Helen J. Lachmann(Royal Free London NHS Foundation Trust), Philip N. Hawkins(The Royal Free Hospital), David R. Booth(Hammersmith Hospital), Janet A. Gilbertson(Children's Cancer and Leukaemia Group), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Mark B. Pepys(Hammersmith Hospital), A Bybee(Amyloidosis Foundation), Susanne E. Booth(Amyloidosis Foundation)
Cited by 686
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
|European Heart Journal|2021|1.1k